What follows is a description of new treatments for acute myelogenous leukemia that are currently in the investigational stages, meaning that they may not yet be available for general use. Discuss these and any other treatment options with your doctor if you are interested in exploring them. Your doctor might recommend you as a candidate for a clinical trial for one of these or another investigational treatment.
Myelotorg: This treatment, which is currently in the investigational phase, combines an antibody that specifically targets leukemia cells, then introduces a toxin into the cells. A potential benefit of this treatment is that it might not produce some of the side effects associated with conventional chemotherapy, such as hair loss and mouth sores. It appears to produce low blood counts, however, and studies thus far suggest that it may not be as effective as conventional chemotherapy in acheiving remission.
Arsenic trioxide: This may be an effective treatment for acute promyelocytic leukemia, one of the subtypes of AML. It has thus far not proven successful in treating other subtypes of AML, however.
Mini-allogeneic stem cell transplantation: This is a new form of stem cell transplantation that is currently being studied. The hope is that it will make stem cell transplantation more suitable for older patients who are otherwise not considered good candidates for a bone marrow transplant. It may not prove to be as effective as full allogeneic transplantation, however.
Immunotherapy: This is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or in a laboratory are used to help boost the body’s natural defenses against cancer. This type of treatment is also referred to as “biologic therapy” and “biotherapy”.
An example of immunotherapy is “monoclonal antibody” therapy. This therapy uses special antibodies that identify substances on cancer cells that cause cancer to grow. The antibodies attach to the substances and kill the cancer cells or block their growth. They may be used by themselves or as an agent to deliver drugs, toxins, or radioactive materials to kill the cancer cells. Monoclonal antibodies are typically administered by infusion (through the vein).
This Web site is sponsored by the law firm of Baron & Budd, P.C. Please understand that the information provided is not medical advice, but is simply offered as a resource to help you learn about acute myelogenous (myeloid) leukemia (AML) and benzene. Please discuss your health-related questions and concerns with your doctor.
Benzene can cause acute myelogenous leukemia and other blood cancers and disorders. If you have been diagnosed with AML and would like information about your legal rights, please call us at 800-946-9646 or e-mail us at
Please also visit our glossary for helpful definitions of medical terms relating to the diagnosis and treatment of AML.
Contact Us for Legal Help
If you or a loved one has AML, NHL, MDS, or Aplastic Anemia and was exposed to benzene or other solvents or chemicals on the job, contact Baron & Budd for a free legal consulation.
First Name:*
Last Name:*
Email Address:*
Address:*
Address 2:
City:*
State* Zip*
Daytime Telephone:*
Evening Telephone:*
The best time to reach me is:*
Daytime Evening
I or a loved one has been diagnosed with:*
I would like an Information Packet and information about the law firm of Baron & Budd, P.C.
I would like a free legal consultation and more information about my legal rights.
Message:
Baron & Budd, P.C. 3102 Oak Lawn Ave Suite 1100 Dallas, TX 75219
